Featured Publications
Vibrational optical coherence tomography detects unique skin fibrotic states: Preliminary results of animal and human studies
Odell ID, Flavell RA, Silver FH. Vibrational optical coherence tomography detects unique skin fibrotic states: Preliminary results of animal and human studies. Journal Of The American Academy Of Dermatology 2020, 85: 780-782. PMID: 32860914, PMCID: PMC9793292, DOI: 10.1016/j.jaad.2020.08.091.Peer-Reviewed Original Research
2023
IL-6 trans-signaling in a humanized mouse model of scleroderma
Odell I, Agrawal K, Sefik E, Odell A, Caves E, Kirkiles-Smith N, Horsley V, Hinchcliff M, Pober J, Kluger Y, Flavell R. IL-6 trans-signaling in a humanized mouse model of scleroderma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306965120. PMID: 37669366, PMCID: PMC10500188, DOI: 10.1073/pnas.2306965120.Peer-Reviewed Original ResearchConceptsBone marrow-derived immune cellsIL-6Human hematopoietic stem cellsImmune cellsT cellsScleroderma skinSoluble IL-6 receptorCD8 T cellsHumanized mouse modelPathogenesis of sclerodermaMesenchymal cellsFibroblast-derived IL-6IL-6 receptorIL-6 signalingT cell activationHuman IL-6Human T cellsExpression of collagenFibrosis improvementPansclerotic morpheaHuman endothelial cellsHumanized miceReduced markersSkin graftsHuman CD4
2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2021
New bullous lesions in a 72-year-old woman
Mendoza H, Goodwin J, Gehlhausen J, Odell I, McNiff J, Gnanapandithan K. New bullous lesions in a 72-year-old woman. Cleveland Clinic Journal Of Medicine 2021, 88: 319-324. PMID: 34078615, DOI: 10.3949/ccjm.88a.20180.Peer-Reviewed Case Reports and Technical Notes
2020
A novel medical student initiative to enhance provision of teledermatology in a resident continuity clinic during the COVID‐19 pandemic: a pilot study
Belzer A, Olamiju B, Antaya RJ, Odell ID, Bia M, Perkins SH, Cohen JM. A novel medical student initiative to enhance provision of teledermatology in a resident continuity clinic during the COVID‐19 pandemic: a pilot study. International Journal Of Dermatology 2020, 60: 128-129. PMID: 33226121, PMCID: PMC7753449, DOI: 10.1111/ijd.15322.Peer-Reviewed Original Research
2019
HER2 joins AKT to inhibit STING immunity
Odell ID, Flavell RA. HER2 joins AKT to inhibit STING immunity. Nature Cell Biology 2019, 21: 917-918. PMID: 31371829, DOI: 10.1038/s41556-019-0368-4.Peer-Reviewed Original Research
2016
Microbiome: Ecology of eczema
Odell ID, Flavell RA. Microbiome: Ecology of eczema. Nature Microbiology 2016, 1: 16135. PMID: 27562264, PMCID: PMC6035744, DOI: 10.1038/nmicrobiol.2016.135.Peer-Reviewed Original ResearchWell-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome
Odell ID, Lilly E, Reeve K, Bosenberg MW, Milstone LM. Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome. JAMA Dermatology 2016, 152: 484. PMID: 26792110, DOI: 10.1001/jamadermatol.2015.4496.Peer-Reviewed Case Reports and Technical NotesCutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib
Shi VJ, Galan A, Odell ID, Choi JN. Cutaneous Vasculopathy as an Adverse Effect of the Anti–Vascular Endothelial Growth Factor Agent Axitinib. JAMA Dermatology 2016, 152: 222. PMID: 26509864, DOI: 10.1001/jamadermatol.2015.3209.Peer-Reviewed Original Research
2015
Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy
Lim YH, Odell ID, Ko CJ, Choate KA. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy. JAMA Dermatology 2015, 151: 1240-1243. PMID: 26422291, DOI: 10.1001/jamadermatol.2015.1925.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor 2Vascular lesionsRamucirumab therapyNon-small cell lung carcinomaExome sequencingNew vascular lesionsMetastatic rectal cancerCell lung carcinomaRich blood supplySomatic mutationsInhibition of angiogenesisVia exome sequencingPotential adverse effectsRight shinAntiangiogenic therapeuticsGrowth factor 2Rectal cancerCombination therapyVascular tumorsGastric adenocarcinomaHistological featuresLung carcinomaBlood supplyRight legIrinotecan hydrochlorideLeukaemic vasculitis with myelodysplastic syndrome
Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. The Lancet 2015, 386: 501-502. PMID: 26251396, DOI: 10.1016/s0140-6736(15)61165-5.Peer-Reviewed Original Research
2014
Optimizing Direct Immunofluorescence
Odell ID, Cook D. Optimizing Direct Immunofluorescence. Methods In Molecular Biology 2014, 1180: 111-117. PMID: 25015144, DOI: 10.1007/978-1-4939-1050-2_6.Peer-Reviewed Original Research
2013
Immunofluorescence Techniques
Odell ID, Cook D. Immunofluorescence Techniques. Journal Of Investigative Dermatology 2013, 133: 1-4. PMID: 23299451, DOI: 10.1038/jid.2012.455.Peer-Reviewed Original Research
2012
Rules of engagement for base excision repair in chromatin
Odell ID, Wallace SS, Pederson DS. Rules of engagement for base excision repair in chromatin. Journal Of Cellular Physiology 2012, 228: 258-266. PMID: 22718094, PMCID: PMC3468691, DOI: 10.1002/jcp.24134.Peer-Reviewed Original ResearchConceptsBase excision repairSingle-strand break repairNucleotide excision repairHomology-directed repairExcision repairCheckpoint activationCell cycle checkpoint activationStrand break repair pathwaysDouble-strand break repair pathwayStrand break repairBreak repair pathwayOxidative damage resultsNucleosome disruptionDNA replicationBreak repairRepair pathwaysDNA segmentsChromatinEfficient repairNumerous DNAOxidative DNA damageRegulatory factorsHuman cellsNucleosomesDNA damage
2011
Nucleosome Disruption by DNA Ligase III-XRCC1 Promotes Efficient Base Excision Repair
Odell ID, Barbour JE, Murphy DL, Della-Maria JA, Sweasy JB, Tomkinson AE, Wallace SS, Pederson DS. Nucleosome Disruption by DNA Ligase III-XRCC1 Promotes Efficient Base Excision Repair. Molecular And Cellular Biology 2011, 31: 4623-4632. PMID: 21930793, PMCID: PMC3209256, DOI: 10.1128/mcb.05715-11.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDeoxyribonuclease (Pyrimidine Dimer)DNADNA DamageDNA GlycosylasesDNA Ligase ATPDNA LigasesDNA Polymerase betaDNA RepairDNA-(Apurinic or Apyrimidinic Site) LyaseDNA-Binding ProteinsHumansLytechinusNucleosomesPoly-ADP-Ribose Binding ProteinsReactive Oxygen SpeciesXenopusXenopus ProteinsX-ray Repair Cross Complementing Protein 1ConceptsBase excision repairNucleosome disruptionApurinic endonucleaseExcision repairEfficient base excision repairNucleated human cellsDNA polymerase βNucleosome substratesRibosomal DNASingle base gapHuman cellsNucleosomesDNA ligasePolymerase βPol βRate-limiting stepHNTH1Ternary complexDNAUnique roleChromatinLigaseDisruptionEndonucleaseLesions form
2009
Non-specific DNA binding interferes with the efficient excision of oxidative lesions from chromatin by the human DNA glycosylase, NEIL1
Odell ID, Newick K, Heintz NH, Wallace SS, Pederson DS. Non-specific DNA binding interferes with the efficient excision of oxidative lesions from chromatin by the human DNA glycosylase, NEIL1. DNA Repair 2009, 9: 134-143. PMID: 20005182, PMCID: PMC2829949, DOI: 10.1016/j.dnarep.2009.11.005.Peer-Reviewed Original Research